Rosetta Genomics (ROSG) Earning Somewhat Favorable Press Coverage, Study Shows

News stories about Rosetta Genomics (NASDAQ:ROSG) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Rosetta Genomics earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.0806771749433 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several research firms have recently issued reports on ROSG. ValuEngine raised shares of Rosetta Genomics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Barrington Research cut shares of Rosetta Genomics from an “outperform” rating to a “market perform” rating in a research report on Monday, December 18th.

How to Become a New Pot Stock Millionaire

Rosetta Genomics stock opened at $0.39 on Tuesday. Rosetta Genomics has a 12-month low of $0.23 and a 12-month high of $3.29. The firm has a market cap of $2.43, a PE ratio of -0.04 and a beta of 0.46.

In related news, major shareholder Healthcare Master Fund Sabby purchased 119,761 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The shares were purchased at an average cost of $0.42 per share, for a total transaction of $50,299.62. The purchase was disclosed in a document filed with the SEC, which is available through this link.

COPYRIGHT VIOLATION WARNING: This story was first published by BBNS and is the property of of BBNS. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://baseballnewssource.com/2018/04/03/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-rosetta-genomics-rosg-stock-price/2010658.html.

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests-based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).

Insider Buying and Selling by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.